Evaluation of anti-liver cancer activity and anticancer mechanism of one novel small molecule compound (THY-10A62) targeting FAK pathway
THY-10A62 demonstrates <i>in vivo</i> antitumor activity against HCC with an acceptable tolerability window, supporting FAK as a viable target. The observed reductions in FAK phosphorylation and changes in BRAF and RASGRF1 phosphorylation suggest pathway-level modulation underlying efficacy. These findings provide preliminary evidence that THY-10A62 is a potential FAK inhibitor for liver cancer therapy and warrant further studies to refine dosing, characterize pharmacokinetics/toxicity, and validate efficacy across additional HCC models.
Authors
- Rong Zou (ORCID: https://orcid.org/0000-0003-2284-5111)
- Yuliang Deng (ORCID: https://orcid.org/0009-0001-0119-0016)
- Yiguo Hu (ORCID: https://orcid.org/0000-0002-3973-2140)
- Jian Huang (ORCID: https://orcid.org/0000-0002-1296-9316)
- Wanqiu Huang (ORCID: https://orcid.org/0000-0003-3354-1148)
- Zhaoqi Zhang (ORCID: https://orcid.org/0000-0002-8415-0019)
- Jie Xu (ORCID: https://orcid.org/0009-0009-7766-8598)
- Dongping Zhang (ORCID: https://orcid.org/0000-0001-6743-8945)
- Qian Zhang (ORCID: https://orcid.org/0000-0001-5975-9781)
Institutions
- Shanghai Jiao Tong University (CN)
- Sichuan University (CN)
- Fudan University (CN)
- Shanghai First People's Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-09-01
- DOI
- https://doi.org/10.3389/fonc.2025.1498005
- Primary Topic
- Cancer Mechanisms and Therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Science and Technology Commission of Shanghai Municipality
- Shanghai Jiao Tong University
- Fundamental Research Funds for the Central Universities